Our New FDA-Approved Treatment: Learn More

Open-Label, Single-Arm, Exploratory Cohort Evaluating Safusidenib in Chemotherapy- and Radiotherapy-Naïve Patients With Grade 3 Isocitrate Dehydrogenase 1 (IDH1)-Mutant Oligodendroglioma

Fabio Iwamoto,1,2 John de Groot,3 Macarena de la Fuente,4 David A. Reardon,5 Yuling Cen,6 Piia Thomas,6 Katherine B. Peters7

1Stanford Brain Tumor Center, Palo Alto, CA, USA; 2Affiliation at time of abstract submission: Columbia University Irving Medical Center, New York, NY, USA; 3University of California, San Francisco, CA, USA; 4Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA; 5Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 6Nuvation Bio Inc., New York, NY, USA; 7Duke University Medical Center, Durham, NC, USA

Poster TIP-08
Presented at the Society for Neuro-Oncology Annual Meeting | November 12–15, 2026 | Philadelphia, PA, USA
For more information, please contact Dr Fabio Iwamoto: fiwamoto@stanford.edu

Jump to a section:

Background

  • IDH-mutant oligodendrogliomas are a distinct category of adult-type diffuse glioma per WHO CNS 2021 criteria1
  • IDH inhibitors represent a paradigm shift in neuro-oncology, giving select patients with Grade 2 IDH-mutant glioma their first targeted treatment option2
  • However, standard-of-care treatment for Grade 3 IDH1-mutant oligodendrogliomas remains maximal safe resection followed by RT and CT2,3
    • Although RT and CT prolongs PFS and OS, it can be associated with substantial detrimental short- and long-term impacts for patients2,4–6
    • There is, therefore, an unmet need for effective targeted treatments for Grade 3 IDH1-mutant oligodendroglioma that can delay use of RT/CT after surgery, be better tolerated, and preserve HRQoL for patients
  •  

Rationale

  • Safusidenib is an investigational mutant-IDH1 inhibitor with high potency, selectivity, and blood-brain barrier permeability,7 that has recently been granted fast track designation by the US FDA for treatment of IDH1-mutant glioma8
    • Safusidenib demonstrated encouraging clinical activity and a favorable risk-benefit profile in patients with IDH1-mutant glioma in Phase 1 (NCT03030066) and Phase 2 (NCT04458272) studies, including responses across histological grades and risk groups9,10

    • Safusidenib has also demonstrated encouraging clinical activity in patients with RT/CT-naïve IDH1-mutant glioma in the Phase 2 study10
    • These findings support further evaluation of safusidenib in patients with Grade 3 IDH1-mutant oligodendroglioma

Study Aim

  • This ongoing, open-label, single-arm exploratory cohort of the SIGMA study (NCT05303519) is evaluating the efficacy and safety of safusidenib in RT/CT-naïve patients with Grade 3 IDH1-mutant oligodendroglioma11
  • A preceding dose-finding part of this study confirmed the RP2D of safusidenib as 250 mg BID
  • This cohort study is being conducted in parallel with the ongoing Phase 3, randomized, double-blind SIGMA study (NCT05303519) evaluating maintenance safusidenib vs placebo following RT/CRT and adjuvant TMZ in patients with IDH1-mutant astrocytoma with high grade or high-risk features11

Study Design: Exploratory Cohort (NCT05303519)

aBICR and INV assessed, per RANO 2.0.

Trial Progress

  • The international Phase 3 SIGMA study (NCT05303519) is ongoing, with approximately 80 sites across Australia, Canada, China, France, Germany, Italy, Japan, Spain, Sweden, UK, and USA selected as of October 2026
  • The first patient in the exploratory cohort was enrolled in July 2026

Summary

  • For patients with Grade 3 IDH1-mutant oligodendroglioma, there is an unmet need for effective targeted treatments that can delay use of RT/CT after surgery
  • Safusidenib is an investigational mutant-IDH1 inhibitor with high potency, selectivity, and blood-brain barrier permeability that has shown encouraging efficacy in patients with IDH1-mutant glioma7,9,10
  • This ongoing, open-label, single-arm, exploratory cohort study will evaluate the efficacy and safety of safusidenib in RT/CT-naïve patients with Grade 3 IDH1-mutant oligodendroglioma

Abbreviations

BICR, blinded independent central review; BID, twice daily; CNS, central nervous system; CR, complete response; CRT, chemoradiotherapy; CT, chemotherapy; FACT-Br, Functional Assessment of Cancer Therapy-Brain; FDA, Food and Drug Administration; HRQoL, health-related quality of life; IDH1/2, isocitrate dehydrogenase 1/2; INV, investigator; KPS, Karnofsky Performance Status; MR, minor response; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PO, orally; PR, partial response; QOLIE-10-P, Patient Weighted Quality of Life in Epilepsy Questionnaire; RANO, Response Assessment in Neuro-Oncology; RP2D, recommended Phase 2 dose; RT, radiation therapy; SNO, Society for Neuro-Oncology; TMZ, temozolomide; UK, United Kingdom; USA, United States of America; WHO, World Health Organization.

References

  1. Louis DN, et al. Neuro Oncol 2021;23:1231–1251
  2. Lin MD, et al. NPJ Precis Oncol 2024;8:149
  3. Mohile NA, et al. J Clin Oncol 2022;40:403–426
  4. Blonski M, et al. Front Oncol 2022;12:827897
  5. Cayuela N, et al. Neuro Oncol 2019;21:1470–1479
  6. Cairncross G, et al. J Clin Oncol 2013;31:337–343
  7. Machida Y, et al. Mol Cancer Ther 2020;19:375–383
  8. Nuvation Bio Press Release. Accessed October 1, 2026; https://investors.nuvationbio.com/news/news-details/2026/Nuvation-Bio-Granted-FDA-Fast-Track-Designation-for-Safusidenib-for-Treatment-of-IDH1-Mutant-Glioma/default.aspx
  9. Natsume A, et al. Neuro Oncol 2023;25:326–336
  10. Arakawa Y, et al. Neuro Oncol 2026;28:717–727
  11. ClinicalTrials.gov. NCT05303519. Accessed October 1, 2026; https://clinicaltrials.gov/study/NCT05303519

Acknowledgments

We would like to thank all patients who are participating in this ongoing study, the study investigators, and their staff. This study is sponsored by Nuvation Bio Inc. Medical writing support was provided by Jane Blackburn, PhD, of Ashfield MedComms, an Inizio company, and was funded by Nuvation Bio Inc.

Explore our other publications